Dianthus Therapeutics ( NASDAQ:DNTH ) Full Year 2024 Results Key Financial Results Net loss: US$85.0m (loss widened by... Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

After hours: 25 March at 16:05:10 GMT-4 Loading Chart for DNTH ...

When interest rates are low, small-cap stocks begin to shine and outpace larger companies in value. These stocks are stocks with a market capitalization between $300 million and $3 billion.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies.

After hours: March 26 at 5:10:03 p.m. EDT Loading Chart for TECX ...

After hours: March 25 at 4:05:09 p.m. EDT Loading Chart for DRTS ...